Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.

ABSTRACT:

Background

Neuregulin 1 (NRG1) fusions, which activate ErbB signaling, are rare oncogenic drivers in multiple tumor types. Afatinib is a pan-ErbB family inhibitor that may be an effective treatment for NRG1 fusion-driven tumors.

Patients and methods

This report summarizes pertinent details, including best tumor response to treatment, for six patients with metastatic NRG1 fusion-positive tumors treated with afatinib.

Results

The six cases include four female and two male patients who ranged in age from 34 to 69 years. Five of the cases are patients with lung cancer, including two patients with invasive mucinous adenocarcinoma and three patients with nonmucinous adenocarcinoma. The sixth case is a patient with colorectal cancer. NRG1 fusion partners for the patients wit

SUBMITTER: Cadranel J 

PROVIDER: S-EPMC7794194 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature